Connect Biopharma(CNTB.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Connect Biopharma
CNTB.US
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
1.820 T
CNTB.USMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
D
BiotechnologyIndustry
Industry Ranking273/386
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-102.94%E
    • Profit Margin-27727.90%E
    • Gross Margin100.00%A
  • Growth ScoreE
    • Revenue YoY-99.10%E
    • Net Profit YoY-275.46%E
    • Total Assets YoY-35.19%E
    • Net Assets YoY-48.58%E
  • Cash ScoreD
    • Cash Flow Margin88.62%C
    • OCF YoY-99.10%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio29.04%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Connect Biopharma Holdings (CNTB) Gets a Buy from H.C. Wainwright

    Tip Ranks·
    US
    CNTB
    +4.34%
    US
    XBI
    +1.77%
    US
    BIB
    +2.80%
    Tip Ranks·
    US
    CNTB
    +4.34%
    US
    XBI
    +1.77%
    US
    BIB
    +2.80%

    Connect Biopharma | 8-K: FY2026 Q1 Revenue: USD 169 K

    Earnings Watch·
    US
    CNTB
    +4.34%
    Earnings Watch·
    US
    CNTB
    +4.34%

    Northland Securities Remains a Buy on Connect Biopharma Holdings (CNTB)

    Tip Ranks·
    US
    CNTB
    +4.34%
    US
    SBIO
    +1.63%
    US
    IBB
    +0.87%
    Tip Ranks·
    US
    CNTB
    +4.34%
    US
    SBIO
    +1.63%
    US
    IBB
    +0.87%

    Connect Biopharma | 10-K: FY2025 Revenue: USD 64 K

    Earnings Watch·
    US
    CNTB
    +4.34%
    Earnings Watch·
    US
    CNTB
    +4.34%

    Connect Biopharma Advances Enrolment In Phase 2 Seabreeze STAT Trial For Asthma Drug Rademikibart

    nasdaq·
    US
    CNTB
    +4.34%
    US
    LABU
    +5.01%
    US
    LABD
    -5.26%
    nasdaq·
    US
    CNTB
    +4.34%
    US
    LABU
    +5.01%
    US
    LABD
    -5.26%
    © 2026 Longbridge｜Disclaimer